(Q73204426)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670535%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670535%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670535%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

Zelda R Wasserman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670535%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Matthew E Voss

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670535%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Chu Biao Xue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670535%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Robert J Cherney

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670535%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

David J Nelson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670535%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Karl D Hardman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670535%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Carl P Decicco

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670535%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 March 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670535%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

published in

Chemistry and Biology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670535%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670535%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670535%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

215-223

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670535%20AND%20SRC:MED&resulttype=core&format=json

Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

Therapeutic potential and strategies for inhibiting tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

Processing of tumour necrosis factor-α precursor by metalloproteinases

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

The therapeutic potential of small molecule TACE inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

On the size of the active site in proteases. I. Papain

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d)

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

First structure of a snake venom metalloproteinase: a prototype for matrix metalloproteinases/collagenases

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

Structures of adamalysin II with peptidic inhibitors. Implications for the design of tumor necrosis factor alpha convertase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

Crystal structures of matrilysin-inhibitor complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

The NMR structure of the inhibited catalytic domain of human stromelysin-1

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

Impact of mobility on structure-based drug design for the MMPs

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

AMBER: Assisted model building with energy refinement. A general program for modeling molecules and their interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

Fitting an inhibitor into the active site of thermolysin: a molecular dynamics case study

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2803%2900044-9

7 January 2021

10.1016/S1074-5521(03)00044-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12670535%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference